Cisplatin-Based Combination Therapy for Enhanced Cancer Treatment

IF 3 4区医学 Q2 PHARMACOLOGY & PHARMACY

Current drug targets Pub Date : 2024-04-09 DOI:10.2174/0113894501294182240401060343

Qi Li, Siwei Chen, Xiao Wang, Jia Cai, Hongwu Huang, Shengsong Tang, Dongxiu He

引用次数: 0

Abstract

:: Cisplatin, a primary chemotherapeutic drug, is of great value in the realm of tumor treatment. However, its clinical efficacy is strictly hindered by issues, such as drug resistance, relapse, poor prognosis, and toxicity to normal tissue. Cisplatin-based combination therapy has garnered increasing attention in both preclinical and clinical cancer research for its ability to overcome resistance, reduce toxicity, and enhance anticancer effects. This review examines three primary co-administration strategies of cisplatin-based drug combinations and their respective advantages and disadvantages. Additionally, seven types of combination therapies involving cisplatin are discussed, focusing on their main therapeutic effects, mechanisms in preclinical research, and clinical applications. This review also discusses future prospects and challenges, aiming to offer guidance for the development of optimal cisplatin-based combination therapy regimens for improved cancer treatment.

查看原文本刊更多论文

加强癌症治疗的顺铂联合疗法

::顺铂是一种主要的化疗药物，在肿瘤治疗领域具有重要价值。然而，耐药性、复发、预后不良以及对正常组织的毒性等问题严格阻碍了它的临床疗效。顺铂联合疗法因其克服耐药性、降低毒性和增强抗癌效果的能力，在临床前和临床癌症研究中日益受到关注。本综述探讨了顺铂类复方药物的三种主要联合用药策略及其各自的优缺点。此外，还讨论了七种涉及顺铂的联合疗法，重点关注其主要治疗效果、临床前研究机制和临床应用。本综述还讨论了未来的前景和挑战，旨在为开发基于顺铂的最佳联合疗法方案提供指导，以改善癌症治疗。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current drug targets 医学-药学

CiteScore

6.20

自引率

0.00%

发文量

127

审稿时长

3-8 weeks

期刊介绍： Current Drug Targets aims to cover the latest and most outstanding developments on the medicinal chemistry and pharmacology of molecular drug targets e.g. disease specific proteins, receptors, enzymes, genes. Current Drug Targets publishes guest edited thematic issues written by leaders in the field covering a range of current topics of drug targets. The journal also accepts for publication mini- & full-length review articles and drug clinical trial studies. As the discovery, identification, characterization and validation of novel human drug targets for drug discovery continues to grow; this journal is essential reading for all pharmaceutical scientists involved in drug discovery and development.